NewResearch Grade
Tesamorelin
GHRH analogue for visceral fat reduction
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that extends its stability. It is one of the few peptides with FDA approval (for HIV-associated lipodystrophy) and is studied for its targeted reduction of visceral adipose tissue.
- ✓Reduces visceral adipose tissue (VAT)
- ✓GHRH analogue with enhanced stability
- ✓Stimulates endogenous GH release
- ✓Studied for metabolic syndrome & lipodystrophy
- ✓≥99% purity — HPLC verified
Mechanism of Action
Tesamorelin is a stabilised synthetic analogue of GHRH(1–44) with a trans-3-hexenoic acid group at the N-terminus that protects it from dipeptidyl peptidase IV cleavage. It stimulates pulsatile GH secretion from the pituitary and has been clinically studied for visceral adiposity reduction in HIV-associated lipodystrophy.
For research and educational purposes only. This information is derived from published preclinical and clinical literature and does not constitute medical advice.